Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
COLL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.23 - $42.29
Previous CloseN/A
Volume233.62K
Average Volume (3M)327.92K
Market Cap
$1.19B
Enterprise Value$1.87B
Total Cash (Recent Filing)$197.77M
Total Debt (Recent Filing)$844.21M
Price to Earnings (P/E)36.6
Beta0.41
Next Earnings
Nov 06, 2025EPS Estimate
2.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.68
Shares Outstanding31,502,127
10 Day Avg. Volume452,334
30 Day Avg. Volume327,921
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.56
Enterprise Value/Revenue2.81
Enterprise Value/Gross Profit4.87
Enterprise Value/Ebitda5.60
Forecast
1Y Price Target
$43.00Price Target Upside13.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial PositionIn a testament to COLL's current strong financial position, the company announced a new $150M share buyback authorization.
Jornay GrowthJornay, acquired through the Ironshore Therapeutics transaction, has rapidly emerged as the company’s lead growth driver, with prescriptions growing 42% year-over-year and 15% sequentially.
Market StrategyWith expanded field force coverage, increasing market share, and exclusivity through at least 2032, Jornay remains early in its commercial trajectory and is well-positioned to contribute significantly to COLL's long-term growth.
Bears Say
Generic CompetitionDespite the portfolio being mature, there is a valuation disconnect in COLL's business driven largely by uncertainty around the potential for generic competition on these products.
Seasonal Sales ImpactA small adjustment is made to reflect the expected seasonal slowdown in sales due to Rx re-authorizations and insurance deductible resets.
Collegium Pharmaceutical News
COLL FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was $23.23 and its highest was $42.29 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Collegium Pharmaceutical’s market cap is $1.19B.
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is Nov 06, 2025 which is in 84 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on Aug 07, 2025. The company reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.617 by $0.063.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is 2.03.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 31,502,127 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of $1.68 in its last earnings report, beating expectations of $1.617. Following the earnings report the stock price went up 10.723%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Currently, no hedge funds are holding shares in COLL
Collegium Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.00 (13.58% Upside)
$43.00 (13.58% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 74.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $602.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 5.0%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.31%
12-Months-Change
Fundamentals
Return on Equity
16.16%
Trailing 12-Months
Asset Growth
51.19%
Trailing 12-Months
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
COLL Company Deck
COLL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a strong financial performance with significant revenue growth and successful execution of strategic priorities, particularly with Jornay PM and the pain portfolio. Despite increased operating expenses and a decline in GAAP net income, the overall business outlook remains positive with raised financial guidance and a strong commitment to shareholder value.View all COLL earnings summariesCOLL Stock 12 Month Forecast
Average Price Target
$43.00
▲(13.58% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Ownership Overview
3.44% Insiders
35.71% Mutual Funds
0.68% Other Institutional Investors
34.63% Public Companies and
Individual Investors